Q4 2024 GoodRx Holdings Inc Earnings Call Transcript
Key Points
- GoodRx Holdings Inc (GDRX) reported a 6% year-over-year increase in full-year 2024 revenue, reaching $792.3 million.
- The company achieved a 20% growth in adjusted EBITDA, with a margin expansion of 420 basis points to 32.8%.
- GoodRx's prescription marketplace saw significant growth, with nearly 30 million consumers using the platform in 2024, saving almost $17 billion on medications.
- The company expanded its partnerships with pharma manufacturers, growing from 150 brands in 2023 to over 200 in 2024, and plans to continue this growth.
- GoodRx's integrated savings program (ISP) is driving meaningful savings for consumers and plan sponsors, with plans to expand its reach and impact.
- Subscription revenue declined by 8% due to the sunset of a retailer-specific prescription savings program.
- The company faces challenges in fully rolling out its ISP with major PBM partners, as not all employer customers have opted in.
- GoodRx is experiencing headwinds on monthly active consumers due to retail pharmacy store closures and rationalizations.
- The sales cycle for brand deals in the pharma manufacturer solutions segment is lengthy, which may delay revenue realization.
- There is uncertainty regarding the impact of potential regulatory changes on pharmaceutical marketing, which could affect GoodRx's digital pharma manufacturer solutions.
Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx fourth quarter and full year 2024 earnings call. As a reminder, today's call is being recorded.
I would now like to introduce your host for today's call, Aubrey Reynolds, Director of Investor Relations. Ms. Reynolds, you may begin.
Thank you, Operator. Good morning, everyone, and welcome to GoodRx's earnings conference call for the fourth quarter and full year 2024. Joining me today are Wendy Barnes, our Chief Executive Officer; and Chris McGinnis, our Chief Financial Officer.
Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding management's plans, strategies, goals and objectives, our market opportunity, our anticipated financial performance, underlying trends in our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
